GlassScriptPhysician profile
Chavona Moore
NPI 1235724311
$873.43
in general payments reported to CMS, 2019-2025
14 companies · $423 in 2025
The $423 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $131 · 2022: $186 · 2023: $49.62 · 2024: $83.66 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $556.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $212.31 | 2021-2022 | |
| Novo Nordisk INC | $137.02 | 2022-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $130.04 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $87.29 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $45.23 | 2023-2025 | Breztri |
| Exact Sciences Corporation | $43.00 | 2025 | Cologuard Collection Kit |
| Abbvie INC. | $35.58 | 2025 | |
| Xeris Pharmaceuticals, INC. | $32.45 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.46 | 2022-2024 | Jardiance |
| Amgen INC. | $30.08 | 2023-2025 | Repatha, Evenity, Prolia |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.20 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $26.56 | 2022-2023 | |
| Shield Therapeutics INC | $21.25 | 2025 | |
| Abbott Laboratories | $12.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chavona Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.